Home Alzheimer’s Disease Phase II Study of Pembrolizumab in Advanced Rare Cancers Shows Promise

Phase II Study of Pembrolizumab in Advanced Rare Cancers Shows Promise

Favorable toxicity profiles and antitumor activity seen in a phase II study of pembrolizumab (Keytruda) in patients with advanced rare cancers supports further evaluation of the drug in this patient population.1

The study, published in the Journal for ImmunoTherapy of Cancer, evaluated pembrolizumab in patients with squamous cell carcinoma (SCC) of the skin, adrenocortical carcinoma (ACC), carcinoma of unknown primary (CUP), and paraganglioma-pheochromocytoma.

“Studies such as this one are key since rare cancers collectively accounted for 13% of all new cancer diagnoses and 25% of all cancer-related deaths in adults in 2017,” Aung Naing, MD, associate professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, said in a press release.2 “The 5-year survival rate is 15% to 20% lower than for more common cancers. The poor outcomes…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

please help us fundraise (501c3 non-profit) : braincancer

I work with OurBrainBank, a start-up non-profit dedicated to moving glioblastoma from terminal to treatable, powered by patients.We're a registered 501c3 non-profit in the...

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

I put my feelings in music. : braincancer

Song LinkHi amigos. My 2year old son has been battling cancer for nearly 6 months and this song is just a expression of my...

Recent Comments